Characteristics of Patients With EBV-LPD
| Patient No. . | Age/ Sex . | Pretransplant Diagnosis . | Weeks Post-transplant . | Clonality . | Peak EBV DNA (copies/μg) . | Days With >40,000 Copies Before Dx. . | Treatment (CD3+ cells/kg) . | Response . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 361 | 48/F | MDS | 26 | ND | 4,000 | — | 1 × 106 | NR | D-LPD/ARDS |
| 379 | 6/M | MDS | 9 | ND | 40,000 | 12 | 1 × 106 | NR | D-LPD |
| 380 | 23/F | CML | 8 | Monoclonal | 400,000 | 7 | 1.2 × 105 | NR | D-LPD/GVH |
| 381 | 9/F | MDS | 11 | Monoclonal | 400,000 | 8 | 1.0 × 106 | NR | D-LPD/ARDS |
| 426 | 45/M | AML | 26 | Monoclonal | 400 | — | excision | CR | A-NED |
| 429* | 44/F | ALL | 25 | Monoclonal | 400,000 | 58 | 2 × 105 | CR | A-NED |
| 440 | 46/F | AML | 9 | Monoclonal | 40,000 | 3 | 7 × 105 | CR | D-GVH |
| Patient No. . | Age/ Sex . | Pretransplant Diagnosis . | Weeks Post-transplant . | Clonality . | Peak EBV DNA (copies/μg) . | Days With >40,000 Copies Before Dx. . | Treatment (CD3+ cells/kg) . | Response . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 361 | 48/F | MDS | 26 | ND | 4,000 | — | 1 × 106 | NR | D-LPD/ARDS |
| 379 | 6/M | MDS | 9 | ND | 40,000 | 12 | 1 × 106 | NR | D-LPD |
| 380 | 23/F | CML | 8 | Monoclonal | 400,000 | 7 | 1.2 × 105 | NR | D-LPD/GVH |
| 381 | 9/F | MDS | 11 | Monoclonal | 400,000 | 8 | 1.0 × 106 | NR | D-LPD/ARDS |
| 426 | 45/M | AML | 26 | Monoclonal | 400 | — | excision | CR | A-NED |
| 429* | 44/F | ALL | 25 | Monoclonal | 400,000 | 58 | 2 × 105 | CR | A-NED |
| 440 | 46/F | AML | 9 | Monoclonal | 40,000 | 3 | 7 × 105 | CR | D-GVH |
The clinical features of the 7 patients with EBV-LPD are summarized above.
Abbreviations: AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; ND, not done; GVHD, graft versus host disease; ARDS, adult respiratory distress syndrome; LPD, lymphoproliferative disease; Dx, diagnosis; NED, no evidence of disease; CR, complete remission; NR, no response; A, alive; D, dead.
UPN 429 received donor-derived EBV-specific T cells.